Recommendations for measuring HIV reservoir size in cure-directed clinical trials
- Abdel-Mohsen, Mohamed;
- Richman, Douglas;
- Siliciano, Robert F;
- Nussenzweig, Michel C;
- Howell, Bonnie J;
- Martinez-Picado, Javier;
- Chomont, Nicolas;
- Bar, Katharine J;
- Yu, Xu G;
- Lichterfeld, Mathias;
- Alcami, Jose;
- Hazuda, Daria;
- Bushman, Frederic;
- Siliciano, Janet D;
- Betts, Michael R;
- Spivak, Adam M;
- Planelles, Vicente;
- Hahn, Beatrice H;
- Smith, Davey M;
- Ho, Ya-Chi;
- Buzon, Maria J;
- Gaebler, Christian;
- Paiardini, Mirko;
- Li, Qingsheng;
- Estes, Jacob D;
- Hope, Thomas J;
- Kostman, Jay;
- Mounzer, Karam;
- Caskey, Marina;
- Fox, Lawrence;
- Frank, Ian;
- Riley, James L;
- Tebas, Pablo;
- Montaner, Luis J
- et al.
Published Web Location
https://www.nature.com/articles/s41591-020-1022-1Abstract
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.